Travaux scientifiques

Uzm. Dr. Hakan Taban

54 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Texte intégral en libre accèsSource : OpenAlex

  2. Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15186966 PMID 42795739 Texte intégral en libre accèsSource : ORCID

  3. Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study

    Medicina, 2026

    DOI 10.3390/medicina62091702 PMID 42796309 Texte intégral en libre accèsSource : ORCID

  4. Synchronous Adrenocortical Carcinoma, Renal Cell Carcinoma, and Mediastinal Mature Teratoma with Heterozygous Variants in SMARCA4, APC, and MYBP3: A Case Report

    Journal of Oncological Sciences, 2026

    DOI 10.37047/jos.galenos.2026.2025-10-7 Texte intégral en libre accèsSource : ORCID

  5. Prognostic Significance of SULF2 Expression in Surgically Resected Non-Small Cell Lung Cancer

    Medical sciences (Basel, Switzerland), 2026

    DOI 10.3390/medsci14020215 PMID 42201007 Texte intégral en libre accèsSource : Europe PMC

  6. Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program

    Future Oncology, 2025

    DOI 10.1080/14796694.2025.2570637 PMID 41103123 Texte intégral en libre accèsSource : OpenAlex

  7. Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel

    Medicina, 2025

    DOI 10.3390/medicina61061105 PMID 40572794 4 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  8. Enhancing Treatment Decisions for Advanced Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutations: A Reinforcement Learning Approach

    Cancers, 2025

    DOI 10.3390/cancers17020233 PMID 39858018 1 citation (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  9. Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas

    Journal of Current Hematology & Oncology Research, 2025

    DOI 10.51271/jchor-0062 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  10. Prognostic value of the StAN score in elderly small cell lung cancer

    Scientific Reports, 2025

    DOI 10.1038/s41598-025-08115-x PMID 40604202 Texte intégral en libre accèsSource : OpenAlex

  11. The lactate dehydrogenase-to-albumin ratio is a prognostic biomarker in extensive-stage small-cell lung cancer

    Acta Medica, 2025

    DOI 10.32552/2025.actamedica.1159 Texte intégral en libre accèsSource : OpenAlex

  12. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

    Journal of Chemotherapy, 2024

    DOI 10.1080/1120009x.2024.2403051 PMID 39257075 2 citations (Europe PMC) Source : OpenAlex

  13. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG)

    European Archives of Oto-Rhino-Laryngology, 2024

    DOI 10.1007/s00405-024-08744-4 PMID 38795147 5 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  14. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).

    Journal of Clinical Oncology, 2024

    DOI 10.1200/jco.2024.42.16_suppl.e18004 Source : ORCID

  15. Sonographic Measurements of Rectus Femoris Muscle Thickness Strongly Predict Neutropenia in Cancer Patients Receiving Chemotherapy

    Cancers, 2024

    DOI 10.3390/cancers16051061 PMID 38473418 9 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  16. Challenges in using tumor mutational burden as a post-treatment biomarker

    ESMO Open, 2024

    DOI 10.1016/j.esmoop.2024.103999 PMID 39561622 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  17. 1271P Integrating machine learning prediction and causal inference analysis to unravel determinants of progression in EGFR-mutant, advanced NSCLC

    Annals of Oncology, 2024

    DOI 10.1016/j.annonc.2024.08.1328 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  18. Prognostic and predictive value of tumor infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

    Clinics and Research in Hepatology and Gastroenterology, 2023

    DOI 10.1016/j.clinre.2023.102171 PMID 37352926 19 citations (OpenAlex) Source : OpenAlex

  19. The Prognostic Significance of KIAA1522 Expression in Non-Small-Cell Lung Cancer Patients

    Cureus, 2023

    DOI 10.7759/cureus.44016 PMID 37746394 1 citation (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  20. Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer

    Clinics and Research in Hepatology and Gastroenterology, 2023

    DOI 10.1016/j.clinre.2023.102091 PMID 36738855 Source : OpenAlex

  21. Treatment selection for T4 laryngeal cancer: is organ-preserving approach possible with chemoradiotherapy or is multimodality treatment more effective?

    Journal of Medicine and Palliative Care, 2023

    DOI 10.47582/jompac.1314922 Texte intégral en libre accèsSource : OpenAlex

  22. Prognosis of Liposarcoma Patients in Modern ERA: Single-Center Experience

    South Asian Journal of Cancer, 2022

    DOI 10.1055/s-0042-1755467 PMID 36756104 1 citation (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  23. Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease

    Journal of Clinical Medicine, 2022

    DOI 10.3390/jcm11175171 PMID 36079101 8 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  24. Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report

    Cureus, 2022

    DOI 10.7759/cureus.27828 PMID 36106272 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  25. Prognostic Factors Associated with Locally Advanced Gastric Cancer in Patients Treated with Adjuvant Chemotherapy

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2022-92230 3 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  26. Nivolumab in Metastatic Renal Cell Carcinoma: Results from the Turkish Oncology Group Kidney Cancer Consortium Database

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0717 PMID 34726480 7 citations (Europe PMC) Source : OpenAlex

  27. Nivolumab as second-line treatment and beyond for metastatic renal cell carcinoma: A real-life experience from Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.6_suppl.321 1 citation (OpenAlex) Source : OpenAlex

  28. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma

    Turkish journal of urology, 2021

    DOI 10.5152/tud.2021.20377 PMID 33819441 6 citations (Europe PMC) Texte intégral en libre accèsSource : Europe PMC

  29. Lower prognostic nutritional index is associated with poorer survival in patients receiving immune checkpoint inhibitors

    Biomarkers in medicine, 2021

    DOI 10.2217/bmm-2020-0674 PMID 34397271 8 citations (Europe PMC) Source : Europe PMC

  30. Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-020-05702-8 PMID 32851486 10 citations (Europe PMC) Source : ORCID

  31. PILE: a candidate prognostic score in cancer patients treated with immunotherapy

    Clinical and Translational Oncology, 2021

    DOI 10.1007/s12094-021-02560-6 PMID 33586122 24 citations (Europe PMC) Source : ORCID

  32. Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy

    Supportive Care in Cancer, 2021

    DOI 10.1007/s00520-021-06139-3 PMID 33709186 20 citations (Europe PMC) Source : ORCID

  33. 456P Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.977 2 citations (OpenAlex) Texte intégral en libre accèsSource : OpenAlex

  34. Adjuvant Treatment with Paclitaxel Plus Trastuzumab for Node-Negative Breast Cancer: Real-Life Experience

    Future Oncology, 2021

    DOI 10.2217/fon-2021-0303 PMID 34758639 4 citations (OpenAlex) Source : OpenAlex

  35. Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/10781552211045909 PMID 34628993 2 citations (OpenAlex) Source : OpenAlex

  36. İleri Evre Panreatiko Biliyer Sistem Tümörlerinde Tedavi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2021

    Source : OpenAlex

  37. Abstract PS10-52: Adjuvant treatment with paclitaxel plus trastuzumab for node negative human epidermal growth factor receptor 2-positive breast cancer: Real life experience

    Cancer Research, 2021

    DOI 10.1158/1538-7445.sabcs20-ps10-52 Source : OpenAlex

  38. 173P What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.454 Texte intégral en libre accèsSource : OpenAlex

  39. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219900908 PMID 32054412 9 citations (Europe PMC) Source : OpenAlex

  40. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155219877234 PMID 31566114 10 citations (Europe PMC) Source : ORCID

  41. CANCER EPIDEMIOLOGY IN ELDERLY PATIENTS

    Turkiye Klinikleri eBooks, 2020

    DOI 10.5336/978-625-401-191-7_p1 1 citation (OpenAlex) Source : OpenAlex

  42. Evaluation of emergency department visits in patients treated with immune checkpoint inhibitors.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.15_suppl.e24160 1 citation (OpenAlex) Source : OpenAlex

  43. Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design

    Clinical Colorectal Cancer, 2020

    DOI 10.1016/j.clcc.2020.02.011 PMID 32224043 Source : OpenAlex

  44. 1546P Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.08.2029 Texte intégral en libre accèsSource : OpenAlex

  45. 1763P Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.08.1827 Texte intégral en libre accèsSource : OpenAlex

  46. 98P Low prognostic nutritional index is independently associated with poorer survival in patients receiving immune checkpoint inhibitors

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.10.587 Texte intégral en libre accèsSource : OpenAlex

  47. Yaşlılarda Kanser Epidemiyolojisi

    Turkiye Klinikleri Medical Oncology - Special Topics, 2020

    Source : OpenAlex

  48. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

    Journal of Oncology Pharmacy Practice, 2019

    DOI 10.1177/1078155219883004 PMID 31653193 17 citations (Europe PMC) Source : OpenAlex

  49. Clinical features and prognosis of patients with liposarcoma: Single-center experience.

    Journal of Clinical Oncology, 2019

    DOI 10.1200/jco.2019.37.15_suppl.e22557 Source : OpenAlex

  50. Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital

    Annals of Oncology, 2019

    DOI 10.1093/annonc/mdz261.017 Texte intégral en libre accèsSource : OpenAlex